Q3 EPS Estimates for Cytosorbents Decreased by HC Wainwright

Cytosorbents Corporation (NASDAQ:CTSO) – HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Cytosorbents in a research note issued to investors on Friday, August 7th. HC Wainwright analyst S. Lee now forecasts that the medical research company will earn ($0.04) per share for the quarter, down from their prior forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.04 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.36 on Tuesday. The company has a market cap of $22.75 million, a P/E ratio of -1.25 and a beta of 1.39. The company has a 50-day moving average price of $0.40 and a 200 day moving average price of $0.55. Cytosorbents has a 52 week low of $0.35 and a 52 week high of $1.22. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 4.70.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.The company had revenue of $9.63 million for the quarter, compared to analysts’ expectations of $9.38 million.

Institutional Investors Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently modified their holdings of the company. Avenir Corp raised its position in shares of Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after buying an additional 147,261 shares during the last quarter. CM Management LLC grew its stake in Cytosorbents by 14.6% in the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after acquiring an additional 188,372 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Cytosorbents in the 3rd quarter worth approximately $161,000. Citadel Advisors LLC raised its holdings in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 36,790 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Phillip P. Chan bought 251,136 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $0.40 per share, with a total value of $100,454.40. Following the purchase, the chief executive officer owned 1,734,099 shares of the company’s stock, valued at $693,639.60. This trade represents a 16.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.